Who was in the WNBA Finals in 2014?
The 2014 WNBA Finals was the playoff series for the 2014 season of the Women’s National Basketball Association (WNBA), and the conclusion of the season’s playoffs. The Phoenix Mercury, champions of the Western Conference, faced the Chicago Sky, champions of the Eastern Conference.
What does an exception mean in the WNBA?
(n) “Exception” means an exception to the rule that a Team’s Team Salary may not exceed the Salary Cap. (o) “Expansion Team” means any Team that becomes a member of the WNBA through expansion following the date of this Agreement and commences play during the term of this Agreement.
When does the off season start for the WNBA?
(z) “Off-Season” means the period beginning one day after the last game of a WNBA Season and continuing through the day prior to the first day of the following Season’s training camp.
When did the WNBA collective bargaining agreement start?
(b) “Agreement” means this Collective Bargaining Agreement entered into on March 5, 2014. (c) “Authorized WNBA Footwear Supplier” (or “Authorized Footwear Supplier”) means an entity granted the right by WNBA Enterprises to outfit one or more WNBA players with logo-identified basketball footwear to be worn during WNBA games.
Why was maribavir discontinued in the United States?
Maribavir was discontinued due to adverse events in 41/120 (34%) patients, and 17/41 discontinued due to CMV infections. During the study, 32 (27%) patients died, 4 due to CMV disease. Dysgeusia was the most common TEAE (78/120; 65%) and led to maribavir discontinuation in 1 patient.
What are the results of the maribavir trial?
Results: From July 2012 to December 2014, 120 patients were randomized and treated (40 per dose group): 80/120 (67%) patients achieved undetectable CMV DNA within 6 weeks of treatment (95% confidence interval, 57-75%), with rates of 70%, 63%, and 68%, respectively, for maribavir 400, 800, and 1200 mg twice daily.
How is maribavir used to treat RR CMV?
Maribavir is active against RR CMV strains. Methods: Hematopoietic-cell or solid-organ transplant recipients ≥12 years old with RR CMV infections and plasma CMV deoxyribonucleic acid (DNA) ≥1000 copies/mL were randomized (1:1:1) to twice-daily dose-blinded maribavir 400, 800, or 1200 mg for up to 24 weeks.